The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).
 
Yelena Janjigian
Stock and Other Ownership Interests - Inspirna
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; eChinaHealth; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; Suzhou Liangyihui Network Technology; Talem Health; TotalCME; WebMD; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; WebMD; Zymeworks
Research Funding - Arcus Biosciences (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Giants of Cancer Care; Research to Practice
 
Hanneke Van Laarhoven
Consulting or Advisory Role - Amphera (Inst); Amphera (Inst); Anocca (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Daiichi (Inst); Dragonfly Therapeutics (Inst); MSD Oncology (Inst); Servier
Speakers' Bureau - Astellas Pharma (Inst); BeiGene (Inst); BMS (Inst); Daiichy Sankyo (Inst); Novartis (Inst)
Research Funding - Auristone; Incyte (Inst); Merck KGaA (Inst); ORCA Therapeutics (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Vadim Kozlov
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Adriano Gravina
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); GlaxoSmithKline/Tesaro (Inst); HiFiBiO Therapeutics (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); Sutro Biopharma (Inst)
 
Liane Rapatoni
Speakers' Bureau - Ipsen; Novartis
Other Relationship - AstraZeneca; Daiichi Sankyo; MSD
 
Hirokazu Shoji
Consulting or Advisory Role - Astellas Pharma
Research Funding - AbbVie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Elevation Oncology (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Ralf Hofheinz
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck; MSD; Nordic Bioscience; Roche; Sanofi
 
Li-Tzong Chen
Leadership - ScinoPharm
Honoraria - ACT Genomics; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical; TTY Biopharm
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Ipsen; MSD; Ono Pharmaceutical; Onward Therapeutics; Taivex Therapeutics; TTY Biopharm
Research Funding - ACT genomics (Inst); Ipsen (Inst); Pfizer (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan
 
Hugo Ford
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Daiichi Sankyo; Daiichi Sankyo (Inst); MSD; MSD (Inst)
 
Maxime Chenard-Poirier
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb
Speakers' Bureau - Incyte; Merck; Pfizer
Other Relationship - Amgen (Inst); AstraZeneca (Inst); Merck (Inst); Sanofi (Inst)
 
Victoria de Giorgio-Miller
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yi-Ting Chang
Employment - AstraZeneca
 
Obinna Anadu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jeeyun Lee
Research Funding - AstraZeneca; Merck Sharp & Dohme
(OPTIONAL) Uncompensated Relationships - Immodulon; Mirati Therapeutics; Revolution Medicines; Trutino Biosciences